Results 151 to 160 of about 198,039 (308)

Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP

The Laryngoscope, EarlyView.
ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm ...
Simon R. Best, Aaron D. Friedman, Clark A. Rosen, Robert T. Sataloff, Laura A. Matrka, H. Steven Sims, David E. Rosow, Nabil F. Saba, David G. Lott, Adam M. Klein, Ted Mau, Milan R. Amin, Kathryn A. Wikenheiser‐Brokamp, Scott M. Norberg, Kim McClellan, Geoffrey D. Young, Clint T. Allen, on behalf of the Recurrent Respiratory Papillomatosis Foundation   +17 more
wiley   +1 more source

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

Medicine Bulletin, EarlyView.
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley   +1 more source

359O_PR Efficacy and safety of pembrolizumab (MK-3475) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Subset analyses for Asia-pacific patients in KEYNOTE-012 (KN-012) B2 cohort [PDF]

, 2016
Makoto Tahara, Kei Muro, Yasuhisa Hasegawa, Hyun Cheol Chung, C-C. Lin, Bhumsuk Keam, J. Cheng, Y-J. Bang   +7 more
openalex   +1 more source

Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report

, 2021
Xinjia Ding, Jianguo Zong, Xiang Li, Xiao‐Yan Bai, Bowen Tan, Weibing Sun, Ruoyu Wang, Yan Ding   +7 more
openalex   +2 more sources

Preoperative VEGFR‐TKI Plus ICI Therapy Facilitates 3D‐Guided Cytoreductive Nephron‐Sparing Surgical Feasibility and Immune Remodeling in Advanced Renal Cell Carcinoma

Med Research, EarlyView.
Preoperative VEGFR‐TKI plus ICI therapy in advanced ccRCC normalizes tumor vasculature, enhances CD8⁺ T/B cell infiltration, and promotes TLS maturation, leading to profound tumor microenvironment remodeling. These immunologic changes improve the feasibility of 3D reconstruction‐guided robotic cytoreductive nephron‐sparing surgery, resulting in reduced
Wenhao Xu, Aihetaimujiang Anwaier, Qintao Ge, Siqi Zhou, Xi Tian, Shuxuan Zhu, Guohai Shi, Yu Zhu, Dingwei Ye, Mierxiati Abudurexiti, Hailiang Zhang   +10 more
wiley   +1 more source

Tumor Organoids: Breakthroughs in Clinical Decision Making, Drug Development, and Translational Advances Beyond Conventional Models

Med Research, EarlyView.
ABSTRACT Tumor organoid models are revolutionizing cancer research by bridging the translational gap between conventional two‐dimensional cell cultures and animal models. This Editorial thoroughly explores the fundamental innovations of patient‐derived organoid technology.
Yimao Wu, Ruowei Sun, Gokhan Zengin, Shuai Ren, Meng‐Yao Li   +4 more
wiley   +1 more source

Advances and Prospects of Stereotactic Radiosurgery and Stereotactic Ablative Body Radiotherapy: Evolving Paradigms in Precision Oncology

Med Research, EarlyView.
The graphical abstract outlines the progressive development and impact of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). Technological Evolution illustrates the transition from brachytherapy with single‐dose, LDR/HDR schedules to fractionated radiotherapy, three‐dimensional conformal radiotherapy (3DCRT) and Gamma Knife ...
Jing Zhang, Wenhao Xu, Weiqing Lu, Yingxuan Lin, Luoxi He, Zonglin Lv, Yiliyaer Nuerrula, Zouting, Zhen Zhang, Hailiang Zhang, Xuejun Ma   +10 more
wiley   +1 more source

1082O KEYMAKER-U02 substudy 02C: Neoadjuvant pembrolizumab (pembro) and investigational agents followed by adjuvant pembro for stage IIIB-D melanoma [PDF]

Georgina V. Long, C. Robert, Andrew Hill, C. Gaudy Marqueste, David C. Portnoy, Roni Shapira, Joel E. Cohen, Muhammad A. Khattak, C. Lebbe, Alexander M. Menzies, Gal Markel, Gil Bar‐Sela, W.H. Sharfman, C. Pagès, O. Hamid, Janice M. Mehnert, Jing Nie, M. Kalabis, C. Krepler, R. Dummer   +19 more
openalex   +1 more source

Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer [PDF]

, 2022
Philippe Rochigneux, Aaron Lisberg, Alejandro J. Garcia, Samuel Granjeaud, Anne Madroszyk, Stéphane Fattori, Anthony Gonçalvès, Raynier Devillier, Pauline Maby, Nassim Salem, Laurent Gorvel, Brice Chanez, Jaklin Gukasyan, James Carroll, Jonathan W. Goldman, Anne-Sophie Chrétien, Daniel Olive, Edward B. Garon   +17 more
openalex   +1 more source

The Evolution of Pneumocystis jirovecii Pneumonia Prophylaxis for Pediatric Patients With Extracranial Solid Tumors: A Review of Historical Insights and Future Directions

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pneumocystis jirovecii pneumonia (PJP) remains a modern‐day complication for pediatric patients receiving treatment for extracranial solid tumors (ST), highlighting the need for reconsideration of our current approach toward PJP prophylaxis. This critical review aims to evaluate both universal and risk‐stratified approaches to PJP prophylaxis ...
Kriti Kumar, Denise M. Connolly, Ellen Kellington, Elyse Zelunka, Karla Kerrigan, Furqan Shaikh, Paul C. Nathan, Meredith S. Irwin, Sarah Cohen‐Gogo   +8 more
wiley   +1 more source